Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4835-4842

  Ramanathan Girish, Sandhya ^b   McColm, Juliet ^c   Clements, John M ^d   Taupin, Phil ^c   Barrowcliffe, Sue ^c   Hevizi, John ^c   Safrin, Sharon ^f   Moore, Clive ^c   Patou, Gary ^f   Moser, Heinz ^f   Gadd, Alison ^c   Hoch, Ute ^e   Jiang, Vernon ^f   Lofland, Denene ^f   Johnson, Kirk W ^a  

^a Genesoft Pharmaceuticals Inc   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Vernalis PLC   (United Kingdom)

^d Heptagen   (United Kingdom)

^e Sunesis Pharmaceuticals Inc   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LINEAR SYSTEM; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; RAT; SIDE EFFECT;

ADULT; AMIDOHYDROLASES; ANIMALS; AREA UNDER CURVE; CENTRAL NERVOUS SYSTEM DISEASES; CROSS-OVER STUDIES; DOGS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXAMIC ACIDS; INFUSIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED ICR; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 9644302493     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4835-4842.2004     Document Type: Article

References (18)

1. Azoulay-Dupuis, E., J. Mohler, and J. P. Bédos. 2004. Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob. Agents Chemother. 48:80-85.
2. Boxenbaum, H. 1982. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. 10:201-227.
3. Clements, J. M., R. P. Beckett, A. Brown, G. Catlin, M. Lobell, S. Palan, W. Thomas, M. Whittaker, S. Wood, S. Salama, P. J. Baker, H. F. Rodgers, V. Barynin, D. W. Rice, and M. G. Hunter. 2001. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 45:563-570.
4. Clements, J. M., A. P. Ayscough, K. Keavey, and S. P. East. 2002. Peptide deformylase inhibitors, potential for a new class of broad spectrum antibacterials. Curr. Med. Chem. Anti-Infect. Agents 1:239-249.
5. Davies, S. J., A. P. Ayscough, R. P. Beckett, J. M. Clements, S. Doel, L. M. Pratt, Z. M. Spavold, S. W. Thomas, and M. Whittaker. 2003. Structure-activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2′ and P3′ side chains. Bioorg. Med. Chem. Lett. 13:2715-2718.
6. East, S., R. P. Beckett, D. C. Brookings, J. M. Clements, S. Doel, K. Keavey, G. Pain, H. K. Smith, W. Thomas, A. J. Thompson, R. S. Todd, and M. Whittaker. 2003. Peptide deformylase inhibitors with activity against respiratory tract pathogens. Bioorg. Med. Chem. Lett. 14:59-62.
7. Eskens, F. A., N. C. Levitt, A. Sparreboom, L. Choi, R. Mather, J. Verweij, and A. L. Harris. 2000. Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor. Clin. Cancer Res. 6:431-433.
8. Gross, M., J. Clements, R. P. Beckett, W. Thomas, S. Taylor, D. Lofland, S. Ramanathan-Girish, M. Garcia, S. Difuntorum, U. Hoch, H. Chen, and K. W. Johnson. 2004. Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. J. Antimicrob. Chemother. 53:487-493.
9. Hackbarth, C. J., D. Z. Chen, J. G. Lewis, K. Clark, J. B. Mangold, J. A. Cramer, P. S. Margolis, W. Wang, J. Koehn, C. Wu, S. Lopez, G. Withers III, H. Gu, E. Dunn, R. Kulathila, S.-H. Pan, W. L. Porter, J. Jacobs, J. Trias, D. V. Patel, B. Weidmann, R. J. White, and Z. Yuan. 2002. N-Alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. 46:2752-2764.
10. Hadden, M., and D. Orton. 2004. Trip report: the Screentech World Summit Conference on "Protease Inhibitors," San Diego, California, March 23-26, 2003. Albany Molecular Research, Inc., technical report, vol. 8. [Online.] www.albmolecular.com/features/tekreps/vol08/no14/.
11. Jones, R., and P. Rhomberg. 2003. Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J. Antimicrob. Chemother. 51:157-161.
12. Kollef, M. H., and V. J. Fraser. 2001. Antibiotic resistance in the intensive care unit. Ann. Intern. Med. 134:298-314.
13. Lofland, D., S. Difuntorum, A. Waller, J. M. Clements, M. K. Weaver, J. A. Karlowsky, and K. W. Johnson. 2004. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J. Antimicrob. Chemother. 53:664-668.
14. Low, D. E. 2001. Antimicrobial drug use and resistance among respiratory pathogens in the community. Clin. Infect. Dis. 33(Suppl. 3):S206-S213.
15. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, D.C.
16. Nguyen, K., C. Colton, R. Chakrabarti, M. Zhu, and D. Pei. 2003. Characterization of a human peptide deformylase: implications for antibacterial drug design. Biochemistry 42:9952-9958.
17. Wise, R., J. M. Andrews, and J. Ashby. 2002. In vitro activities of peptide deformylase inhibitors against gram-positive pathogens. Antimicrob. Agents Chemother. 46:1117-1118.
18. Yuan, Z., J. Trias, and R. White. 2001. Deformylase as a novel antibacterial target. Drug Discov. Today 6:954-961.